APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

CAR-T Therapy For B-Cell Malignancies

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CAR-T Therapy For B-Cell Malignancies Market Analysis and Forecast 2026-2032

Report ID 173974770223 December 2025209 pages

Choose your research edition.

Industry ResearchCAR-T Therapy For B-Cell Malignancies Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR-T Therapy For B-Cell Malignancies Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CAR-T Therapy For B-Cell Malignancies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR-T Therapy For B-Cell Malignancies Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR-T Therapy For B-Cell Malignancies Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global CAR-T Therapy For B-Cell Malignancies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CAR-T Therapy For B-Cell Malignancies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CAR-T Therapy For B-Cell Malignancies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CAR-T Therapy For B-Cell Malignancies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CAR-T Therapy For B-Cell Malignancies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CAR-T Therapy For B-Cell Malignancies include IMCURE, JW Therapeutics, Johnson And Johnson, Novartis, Roche, CARsgen Therapeutics, Chongqing Precision Biotech, Gilead Sciences and HEBECELL, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CAR-T Therapy For B-Cell Malignancies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CAR-T Therapy For B-Cell Malignancies, also provides the revenue of main regions and countries. Of the upcoming market potential for CAR-T Therapy For B-Cell Malignancies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CAR-T Therapy For B-Cell Malignancies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CAR-T Therapy For B-Cell Malignancies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CAR-T Therapy For B-Cell Malignancies revenue, projected growth trends, production technology, application and end-user industry.

CAR-T Therapy For B-Cell Malignancies Segment by Company

IMCURE

JW Therapeutics

Johnson And Johnson

Novartis

Roche

CARsgen Therapeutics

Chongqing Precision Biotech

Gilead Sciences

HEBECELL

Fosun Kite Bio

Legend Biotech

Beihai Biotechnology

AstraZeneca

Regeneron Pharmaceuticals

Kite Pharma

Celgene

Bristol Myers Squibb

Bluebird Bio

CAR-T Therapy For B-Cell Malignancies Segment by Type

Universal CAR-T

Dual Targets CAR-T

Gene Modified Enhanced CAR-T

Multi Targets CAR-T

Single Target CAR-T

CAR-T Therapy For B-Cell Malignancies Segment by Application

Multiple Myeloma

B-Cell Acute Lymphoblastic Leukemia

B-Cell Non-Hodgkin's Lymphoma

Others

CAR-T Therapy For B-Cell Malignancies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR-T Therapy For B-Cell Malignancies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR-T Therapy For B-Cell Malignancies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR-T Therapy For B-Cell Malignancies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CAR-T Therapy For B-Cell Malignancies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CAR-T Therapy For B-Cell Malignancies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR-T Therapy For B-Cell Malignancies revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Universal CAR-T Major Player Table 3. Dual Targets CAR-T Major Player Table 4. Gene Modified Enhanced CAR-T Major Player Table 5. Multi Targets CAR-T Major Player Table 6. Single Target CAR-T Major Player Table 7. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Multiple Myeloma Major Player Table 9. B-Cell Acute Lymphoblastic Leukemia Major Player Table 10. B-Cell Non-Hodgkin's Lymphoma Major Player Table 11. Others Major Player Table 12. CAR-T Therapy For B-Cell Malignancies Industry Trends Table 13. CAR-T Therapy For B-Cell Malignancies Industry Drivers Table 14. CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges Table 15. CAR-T Therapy For B-Cell Malignancies Industry Restraints Table 16. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2021-2026) & (US$ Million) Table 18. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2021-2026) Table 19. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2027-2032) & (US$ Million) Table 20. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2027-2032) Table 21. Global CAR-T Therapy For B-Cell Malignancies Revenue by Players (US$ Million) & (2021-2026) Table 22. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Players (2021-2026) Table 23. Global CAR-T Therapy For B-Cell Malignancies Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global CAR-T Therapy For B-Cell Malignancies Key Players Headquarters & Area Served Table 25. Global CAR-T Therapy For B-Cell Malignancies Players, Product Type & Application Table 26. Global CAR-T Therapy For B-Cell Malignancies Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global CAR-T Therapy For B-Cell Malignancies by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global CAR-T Therapy For B-Cell Malignancies Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026) & (US$ Million) Table 31. Global CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032) & (US$ Million) Table 32. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2021-2026) Table 33. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2027-2032) Table 34. Global CAR-T Therapy For B-Cell Malignancies Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026) & (US$ Million) Table 36. Global CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032) & (US$ Million) Table 37. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2021-2026) Table 38. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2027-2032) Table 39. IMCURE Company Information Table 40. IMCURE Business Overview Table 41. IMCURE CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 43. IMCURE Recent Development Table 44. JW Therapeutics Company Information Table 45. JW Therapeutics Business Overview Table 46. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 48. JW Therapeutics Recent Development Table 49. Johnson And Johnson Company Information Table 50. Johnson And Johnson Business Overview Table 51. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 53. Johnson And Johnson Recent Development Table 54. Novartis Company Information Table 55. Novartis Business Overview Table 56. Novartis CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 58. Novartis Recent Development Table 59. Roche Company Information Table 60. Roche Business Overview Table 61. Roche CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 63. Roche Recent Development Table 64. CARsgen Therapeutics Company Information Table 65. CARsgen Therapeutics Business Overview Table 66. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 68. CARsgen Therapeutics Recent Development Table 69. Chongqing Precision Biotech Company Information Table 70. Chongqing Precision Biotech Business Overview Table 71. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 73. Chongqing Precision Biotech Recent Development Table 74. Gilead Sciences Company Information Table 75. Gilead Sciences Business Overview Table 76. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 78. Gilead Sciences Recent Development Table 79. HEBECELL Company Information Table 80. HEBECELL Business Overview Table 81. HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 83. HEBECELL Recent Development Table 84. Fosun Kite Bio Company Information Table 85. Fosun Kite Bio Business Overview Table 86. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 88. Fosun Kite Bio Recent Development Table 89. Legend Biotech Company Information Table 90. Legend Biotech Business Overview Table 91. Legend Biotech CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 93. Legend Biotech Recent Development Table 94. Beihai Biotechnology Company Information Table 95. Beihai Biotechnology Business Overview Table 96. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 98. Beihai Biotechnology Recent Development Table 99. AstraZeneca Company Information Table 100. AstraZeneca Business Overview Table 101. AstraZeneca CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 103. AstraZeneca Recent Development Table 104. Regeneron Pharmaceuticals Company Information Table 105. Regeneron Pharmaceuticals Business Overview Table 106. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 108. Regeneron Pharmaceuticals Recent Development Table 109. Kite Pharma Company Information Table 110. Kite Pharma Business Overview Table 111. Kite Pharma CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 113. Kite Pharma Recent Development Table 114. Celgene Company Information Table 115. Celgene Business Overview Table 116. Celgene CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 118. Celgene Recent Development Table 119. Bristol Myers Squibb Company Information Table 120. Bristol Myers Squibb Business Overview Table 121. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 123. Bristol Myers Squibb Recent Development Table 124. Bluebird Bio Company Information Table 125. Bluebird Bio Business Overview Table 126. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 128. Bluebird Bio Recent Development Table 129. North America CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026) & (US$ Million) Table 130. North America CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032) & (US$ Million) Table 131. North America CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026) & (US$ Million) Table 132. North America CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032) & (US$ Million) Table 133. North America CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. North America CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021-2026) & (US$ Million) Table 135. North America CAR-T Therapy For B-Cell Malignancies Revenue by Country (US$ Million) & (2027-2032) Table 136. Europe CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026) & (US$ Million) Table 137. Europe CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032) & (US$ Million) Table 138. Europe CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026) & (US$ Million) Table 139. Europe CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032) & (US$ Million) Table 140. Europe CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. Europe CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021-2026) & (US$ Million) Table 142. Europe CAR-T Therapy For B-Cell Malignancies Revenue by Country (US$ Million) & (2027-2032) Table 143. China CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026) & (US$ Million) Table 144. China CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032) & (US$ Million) Table 145. China CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026) & (US$ Million) Table 146. China CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032) & (US$ Million) Table 147. Asia CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026) & (US$ Million) Table 148. Asia CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032) & (US$ Million) Table 149. Asia CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026) & (US$ Million) Table 150. Asia CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032) & (US$ Million) Table 151. Asia CAR-T Therapy For B-Cell Malignancies Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Asia CAR-T Therapy For B-Cell Malignancies Revenue by Region (US$ Million) & (2021-2026) Table 153. Asia CAR-T Therapy For B-Cell Malignancies Revenue by Region (US$ Million) & (2027-2032) Table 154. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026) & (US$ Million) Table 155. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032) & (US$ Million) Table 156. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026) & (US$ Million) Table 157. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032) & (US$ Million) Table 158. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021-2026) & (US$ Million) Table 160. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Country (US$ Million) & (2027-2032) Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. CAR-T Therapy For B-Cell Malignancies Image Figure 2. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CAR-T Therapy For B-Cell Malignancies Market Size Share 2021 VS 2025 VS 2032 Figure 4. Universal CAR-T Image Figure 5. Dual Targets CAR-T Image Figure 6. Gene Modified Enhanced CAR-T Image Figure 7. Multi Targets CAR-T Image Figure 8. Single Target CAR-T Image Figure 9. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global CAR-T Therapy For B-Cell Malignancies Market Size Share 2021 VS 2025 VS 2032 Figure 11. Multiple Myeloma Image Figure 12. B-Cell Acute Lymphoblastic Leukemia Image Figure 13. B-Cell Non-Hodgkin's Lymphoma Image Figure 14. Others Image Figure 15. Global CAR-T Therapy For B-Cell Malignancies Market Size (US$ Million) & (2021-2032) Figure 16. Global CAR-T Therapy For B-Cell Malignancies Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global CAR-T Therapy For B-Cell Malignancies Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2021-2032) Figure 23. Global CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2021-2032) Figure 26. North America CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032) Figure 28. North America CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032) Figure 29. North America CAR-T Therapy For B-Cell Malignancies Revenue Share by Country (2021-2032) Figure 30. United States CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032) Figure 35. Europe CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032) Figure 36. Europe CAR-T Therapy For B-Cell Malignancies Revenue Share by Country (2021-2032) Figure 37. Germany CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032) Figure 47. China CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032) Figure 48. Asia CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032) Figure 50. Asia CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032) Figure 51. Asia CAR-T Therapy For B-Cell Malignancies Revenue Share by Region (2021-2032) Figure 52. Japan CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032) Figure 60. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032) Figure 61. SAMEA CAR-T Therapy For B-Cell Malignancies Revenue Share by Country (2021-2032) Figure 62. Brazil CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt CAR-T Therapy For B-Cell Malignancies Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Universal CAR-T
  • Dual Targets CAR-T
  • Gene Modified Enhanced CAR-T
  • Multi Targets CAR-T
  • Single Target CAR-T
Applications
  • Multiple Myeloma
  • B-Cell Acute Lymphoblastic Leukemia
  • B-Cell Non-Hodgkin's Lymphoma
  • Others
Companies covered
  • IMCURE
  • JW Therapeutics
  • Johnson And Johnson
  • Novartis
  • Roche
  • CARsgen Therapeutics
  • Chongqing Precision Biotech
  • Gilead Sciences
  • HEBECELL
  • Fosun Kite Bio
  • Legend Biotech
  • Beihai Biotechnology
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Kite Pharma
  • Celgene
  • Bristol Myers Squibb
  • Bluebird Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CAR-T Therapy For B-Cell Malignancies Market by Type
  3. 1.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Universal CAR-T
  5. 1.2.3 Dual Targets CAR-T
  6. 1.2.4 Gene Modified Enhanced CAR-T
  7. 1.2.5 Multi Targets CAR-T
  8. 1.2.6 Single Target CAR-T
  9. 1.3 CAR-T Therapy For B-Cell Malignancies Market by Application
  10. 1.3.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Multiple Myeloma
  12. 1.3.3 B-Cell Acute Lymphoblastic Leukemia
  13. 1.3.4 B-Cell Non-Hodgkin's Lymphoma
  14. 1.3.5 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 CAR-T Therapy For B-Cell Malignancies Market Dynamics
  1. 2.1 CAR-T Therapy For B-Cell Malignancies Industry Trends
  2. 2.2 CAR-T Therapy For B-Cell Malignancies Industry Drivers
  3. 2.3 CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges
  4. 2.4 CAR-T Therapy For B-Cell Malignancies Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CAR-T Therapy For B-Cell Malignancies Market Perspective (2021-2032)
  2. 3.2 Global CAR-T Therapy For B-Cell Malignancies Growth Trends by Region
  3. 3.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2021-2026)
  5. 3.2.3 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CAR-T Therapy For B-Cell Malignancies Revenue by Players
  2. 4.1.1 Global CAR-T Therapy For B-Cell Malignancies Revenue by Players (2021-2026)
  3. 4.1.2 Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CAR-T Therapy For B-Cell Malignancies Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CAR-T Therapy For B-Cell Malignancies Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CAR-T Therapy For B-Cell Malignancies Key Players Headquarters & Area Served
  7. 4.4 Global CAR-T Therapy For B-Cell Malignancies Players, Product Type & Application
  8. 4.5 Global CAR-T Therapy For B-Cell Malignancies Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CAR-T Therapy For B-Cell Malignancies Market CR5 and HHI
  11. 4.6.3 2025 CAR-T Therapy For B-Cell Malignancies Tier 1, Tier 2, and Tier 3
5 CAR-T Therapy For B-Cell Malignancies Market Size by Type
  1. 5.1 Global CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2032)
  3. 5.3 Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2021-2032)
6 CAR-T Therapy For B-Cell Malignancies Market Size by Application
  1. 6.1 Global CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2032)
  3. 6.3 Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 IMCURE
  2. 7.1.1 IMCURE Company Information
  3. 7.1.2 IMCURE Business Overview
  4. 7.1.3 IMCURE CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  5. 7.1.4 IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio
  6. 7.1.5 IMCURE Recent Developments
  7. 7.2 JW Therapeutics
  8. 7.2.1 JW Therapeutics Company Information
  9. 7.2.2 JW Therapeutics Business Overview
  10. 7.2.3 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  11. 7.2.4 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  12. 7.2.5 JW Therapeutics Recent Developments
  13. 7.3 Johnson And Johnson
  14. 7.3.1 Johnson And Johnson Company Information
  15. 7.3.2 Johnson And Johnson Business Overview
  16. 7.3.3 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio
  18. 7.3.5 Johnson And Johnson Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 CARsgen Therapeutics
  32. 7.6.1 CARsgen Therapeutics Company Information
  33. 7.6.2 CARsgen Therapeutics Business Overview
  34. 7.6.3 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  35. 7.6.4 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  36. 7.6.5 CARsgen Therapeutics Recent Developments
  37. 7.7 Chongqing Precision Biotech
  38. 7.7.1 Chongqing Precision Biotech Company Information
  39. 7.7.2 Chongqing Precision Biotech Business Overview
  40. 7.7.3 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  42. 7.7.5 Chongqing Precision Biotech Recent Developments
  43. 7.8 Gilead Sciences
  44. 7.8.1 Gilead Sciences Company Information
  45. 7.8.2 Gilead Sciences Business Overview
  46. 7.8.3 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio
  48. 7.8.5 Gilead Sciences Recent Developments
  49. 7.9 HEBECELL
  50. 7.9.1 HEBECELL Company Information
  51. 7.9.2 HEBECELL Business Overview
  52. 7.9.3 HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  53. 7.9.4 HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio
  54. 7.9.5 HEBECELL Recent Developments
  55. 7.10 Fosun Kite Bio
  56. 7.10.1 Fosun Kite Bio Company Information
  57. 7.10.2 Fosun Kite Bio Business Overview
  58. 7.10.3 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  60. 7.10.5 Fosun Kite Bio Recent Developments
  61. 7.11 Legend Biotech
  62. 7.11.1 Legend Biotech Company Information
  63. 7.11.2 Legend Biotech Business Overview
  64. 7.11.3 Legend Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  66. 7.11.5 Legend Biotech Recent Developments
  67. 7.12 Beihai Biotechnology
  68. 7.12.1 Beihai Biotechnology Company Information
  69. 7.12.2 Beihai Biotechnology Business Overview
  70. 7.12.3 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio
  72. 7.12.5 Beihai Biotechnology Recent Developments
  73. 7.13 AstraZeneca
  74. 7.13.1 AstraZeneca Company Information
  75. 7.13.2 AstraZeneca Business Overview
  76. 7.13.3 AstraZeneca CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio
  78. 7.13.5 AstraZeneca Recent Developments
  79. 7.14 Regeneron Pharmaceuticals
  80. 7.14.1 Regeneron Pharmaceuticals Company Information
  81. 7.14.2 Regeneron Pharmaceuticals Business Overview
  82. 7.14.3 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio
  84. 7.14.5 Regeneron Pharmaceuticals Recent Developments
  85. 7.15 Kite Pharma
  86. 7.15.1 Kite Pharma Company Information
  87. 7.15.2 Kite Pharma Business Overview
  88. 7.15.3 Kite Pharma CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio
  90. 7.15.5 Kite Pharma Recent Developments
  91. 7.16 Celgene
  92. 7.16.1 Celgene Company Information
  93. 7.16.2 Celgene Business Overview
  94. 7.16.3 Celgene CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio
  96. 7.16.5 Celgene Recent Developments
  97. 7.17 Bristol Myers Squibb
  98. 7.17.1 Bristol Myers Squibb Company Information
  99. 7.17.2 Bristol Myers Squibb Business Overview
  100. 7.17.3 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio
  102. 7.17.5 Bristol Myers Squibb Recent Developments
  103. 7.18 Bluebird Bio
  104. 7.18.1 Bluebird Bio Company Information
  105. 7.18.2 Bluebird Bio Business Overview
  106. 7.18.3 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  108. 7.18.5 Bluebird Bio Recent Developments
8 North America
  1. 8.1 North America CAR-T Therapy For B-Cell Malignancies Revenue (2021-2032)
  2. 8.2 North America CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2032)
  3. 8.2.1 North America CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026)
  4. 8.2.2 North America CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032)
  5. 8.3 North America CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032)
  6. 8.4 North America CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2032)
  7. 8.4.1 North America CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026)
  8. 8.4.2 North America CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032)
  9. 8.5 North America CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032)
  10. 8.6 North America CAR-T Therapy For B-Cell Malignancies Revenue by Country
  11. 8.6.1 North America CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021-2026)
  13. 8.6.3 North America CAR-T Therapy For B-Cell Malignancies Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe CAR-T Therapy For B-Cell Malignancies Revenue (2021-2032)
  2. 9.2 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2032)
  3. 9.2.1 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026)
  4. 9.2.2 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032)
  5. 9.3 Europe CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032)
  6. 9.4 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2032)
  7. 9.4.1 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026)
  8. 9.4.2 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032)
  9. 9.5 Europe CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032)
  10. 9.6 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Country
  11. 9.6.1 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021-2026)
  13. 9.6.3 Europe CAR-T Therapy For B-Cell Malignancies Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China CAR-T Therapy For B-Cell Malignancies Revenue (2021-2032)
  2. 10.2 China CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2032)
  3. 10.2.1 China CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026)
  4. 10.2.2 China CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032)
  5. 10.3 China CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032)
  6. 10.4 China CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2032)
  7. 10.4.1 China CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026)
  8. 10.4.2 China CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032)
  9. 10.5 China CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CAR-T Therapy For B-Cell Malignancies Revenue (2021-2032)
  2. 11.2 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2032)
  3. 11.2.1 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026)
  4. 11.2.2 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032)
  5. 11.3 Asia CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032)
  6. 11.4 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2032)
  7. 11.4.1 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026)
  8. 11.4.2 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032)
  9. 11.5 Asia CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032)
  10. 11.6 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Country
  11. 11.6.1 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021-2026)
  13. 11.6.3 Asia CAR-T Therapy For B-Cell Malignancies Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue (2021-2032)
  2. 12.2 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Type (2027-2032)
  5. 12.3 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Application (2027-2032)
  9. 12.5 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Country
  11. 12.6.1 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CAR-T Therapy For B-Cell Malignancies Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst